Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fallback tests in dose-response clinical trials.

Alex Dmitrienko1, Brian Wiens, Peter Westfall

  • 1Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. dmitrienko_alex@lilly.com

Journal of Biopharmaceutical Statistics
|October 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.

Annals of the rheumatic diseases·2025
Same author

Modern approaches for evaluating treatment effect heterogeneity from clinical trials and observational data.

Statistics in medicine·2024
Same author

Overview of modern approaches for identifying and evaluating heterogeneous treatment effects from clinical data.

Clinical trials (London, England)·2023
Same author

Quantitative MRI Biomarkers as Potential Inclusion Body Myositis Clinical Trial Endpoints.

Neurology·2022
Same author

A two-stage adaptive clinical trial design with data-driven subgroup identification at interim analysis.

Pharmaceutical statistics·2022
Same author

Data-Driven Subgroup Identification in Confirmatory Clinical Trials.

Therapeutic innovation & regulatory science·2021
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

A new multi-stage fallback procedure enhances dose-response trial analysis by improving dose-control comparisons and managing multiple endpoints. This method offers increased statistical power and controls Type I error rates effectively.

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Statistical Methods

Background:

  • Dose-response trials are crucial for evaluating drug efficacy and safety.
  • Existing methods for dose-control comparisons can be limited, especially with multiple endpoints.
  • Handling multiplicity in statistical testing is a key challenge in clinical trials.

Purpose of the Study:

  • To introduce a novel multi-stage fallback procedure for dose-control comparisons in dose-response trials.
  • To extend the existing fallback test to accommodate one or more endpoints.
  • To provide an efficient method for managing statistical multiplicity arising from multiple endpoints.

Main Methods:

  • The proposed method is a multi-stage fallback procedure, extending Wiens' (2003) fallback test.

Related Experiment Videos

  • It incorporates a simple stepwise approach that considers dose ordering.
  • The procedure is formulated as a closed testing procedure to control Type I error rates.

    • Main Results:

    • The multi-stage fallback procedure improves the power of dose-control tests, particularly at higher doses.
    • It efficiently handles multiplicity associated with multiple endpoints.
    • The procedure maintains control of the Type I error rate across multiple dose-control comparisons and endpoints.

    Conclusions:

    • The multi-stage fallback procedure offers a robust and efficient statistical framework for dose-response trials.
    • This method enhances the analysis of trials with single or multiple endpoints.
    • It provides a reliable approach for dose-control comparisons, increasing statistical power and maintaining error rate control.